Back to discover
Disease
Osteogenesis Imperfecta
Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
12
Associated genes
1
Related proteins
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Update on the Genetics of Osteogenesis Imperfecta.
Research2024-08-11Calcified tissue international
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027An Open-label Phase 3 Study of Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Type I, III, or IV
- Q1 2027Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study
- Q2 2027A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
- Q4 2027A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)
- Q2 2028A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20272026-06-15
Upcoming trial readoutHigh impact
Results expected Q2 20272026-05-27
Clinical MilestonesViewHide
Results expected
- 2026-07-09A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)Results expected Q4 2027
- 2026-06-22A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis ImperfectaResults expected Q2 2028
- 2026-06-15An Open-label Phase 3 Study of Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Type I, III, or IVResults expected Q1 2027
- 2026-05-27A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaResults expected Q2 2027
- 2026-04-28Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot StudyResults expected Q1 2027
Recently completed
Activity timeline6
- 2026-07-09ClinicalA Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)Results expected Q4 2027
- 2026-06-22ClinicalA Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis ImperfectaResults expected Q2 2028
- 2026-06-15ClinicalAn Open-label Phase 3 Study of Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Type I, III, or IVResults expected Q1 2027
- 2026-05-27ClinicalA Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaResults expected Q2 2027
- 2026-04-28ClinicalEffects of Bisphosphonates on OI-Related Hearing Loss: A Pilot StudyResults expected Q1 2027
- 2025-10-23ClinicalAn Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IVPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
12
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes1
- Osteogenesis Imperfecta1
Leading journals1
- Calcified tissue international1
Leading researchers2
- Jovanovic M1
- Marini JC1
Affiliations (unnormalised)1
- Eunice Kennedy Shriver National Institute of Child Health and Human Development1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.